Coccidioidomycosis: efficacy of new agents and future prospects.
Recent studies have contributed to our understanding of risk factors for severe and potentially life-threatening infections with Coccidioides immitis, allowing a more rational approach to initiation of antifungal therapy for this infection, as well as determining its intensity and duration. A large randomized trial found that itraconazole and fluconazole had similar efficacies in the treatment of progressive nonmeningeal coccidioidomycosis. An animal model of coccidioidal meningitis suggested potential efficacy of systemically administered liposomal amphotericin B. Investigational agents that have activity against C. immitis include posaconazole, voriconazole, caspofungin, and sordarin derivatives.
Deresinski
S C
SC
Department of Medicine, Stanford University, Stanford, California, USA. polishmd@earthlink.net
D000935:Antifungal Agents / Q000627:therapeutic use*; D003047:Coccidioidomycosis / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors
D000935:Antifungal Agents